Gilead Board of Directors Approves Two-for-One Stock Split

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 8, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its Board of Directors has approved a two-for-one stock split of the company's outstanding common stock to be effected through a stock dividend. Stockholders of record as of the close of business on May 24, 2007 will receive a stock dividend of one additional share of common stock for every share of common stock they own. Based on the total number of shares of common stock outstanding as of March 31, 2007, the stock split will increase the total number of shares of common stock outstanding from approximately 465,544,000 to 931,088,000, out of the 1,400,000,000 shares of common stock currently authorized.

Because Gilead will establish a Direct Registration System for its stockholders prior to the dividend distribution date, the company's transfer agent, Mellon Investor Services L.L.C., has been instructed to mail a Direct Registration Transaction Advice for the additional shares to stockholders that have physical possession of their stock certificates on June 22, 2007. Stockholders who hold their stock in a brokerage account will receive their new shares through their broker dealer on or about the same date. For more information or for questions, please contact Mellon Investor Services directly at 800-710-0940. The company's stock will begin trading at the post-split price on June 25, 2007. Any shares purchased after May 24, 2007 through June 22, 2007 will come with a "due-bill" entitling the buyer to one additional share for each share purchased.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.